Table 16:

Overview of Study Population and Groups in MRD-HR Patients in UKALL2003 Trial

						Sample Size
Patients	No. of Study Sites	Outcomes	ALL Type(s)	Age, Years (MD, IQR)	% Male	Augmented	Standard
MRD-HR	46	1: EFSa, OS 2: CIR, TR toxic effects	B-cell 86.1% T-cell 13.9%	5 (3–10)	55.5	267	266

Abbreviations: ALL, acute lymphoblastic leukemia; CIR, cumulative incidence of relapse; EFS, event-free survival; IQR, interquartile range; MD, median; MRD-HR, minimal residual disease–high risk; No., number; OS, overall survival; TR, treatment-related.

^aEvents included relapse, secondary tumour, or death.

Source: Vora et al, 2014.⁶⁸